Milan

• A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended recruitment
  2022-502100-70-00 10 2021-06-23 Participants with Microsatellite Instability-High (MSI-H) or Mismatch
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended recruitment
  2024-514473-21-00 5 2021-06-21 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended recruitment
  2023-508738-32-00 4 2021-06-16 Previously untreated and histologically confirmed HER2-Positive (HER2
• Study of BGB-11417 in Patients with Mature B Cell Malignancies Ended recruitment
  2024-515592-35-00 1 2021-06-14 Mature B Cell Malignancies
• A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr … Ended recruitment
  2024-510588-53-00 11 2021-06-10 Treatment of patients with HER2-positive breast cancer with or without
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive … Ended recruitment
  2023-505249-24-00 5 2021-05-27 HER2-positive metastatic breast cancer
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended recruitment
  2023-507132-21-00 10 2021-05-11 Early Parkinson's disease
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa … Ended recruitment
  2024-516868-28-00 4 2021-05-04 Ph+ Acute Lymphoblastic Leukemia
• DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended recruitment
  2023-509865-19-00 5 2021-04-30 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended recruitment
  2023-505615-21-00 5 2021-04-28 Muscle Invasive Bladder Cancer
• Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended recruitment
  2024-511934-11-00 4 2021-04-27 Previously treated unresectable or metastatic BRAFV600 or NRAS mutant
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M … Ended recruitment
  2023-507188-21-00 5 2021-04-20 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies. Ended recruitment
  2023-509781-37-00 7 2021-04-12 Nectin-4 Expressing Advanced Malignancies.
• Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexande … Ended recruitment
  2024-510603-11-00 7 2021-04-08 Alexander Disease
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac … Ended recruitment
  2024-514467-26-00 4 2021-04-07 Indolent Systemic Mastocytosis
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)

Showing 1,633–1,656 of 2,361 trials